Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.» Read More
The National Kidney Foundation said on Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.
Genentech said first-quarter earnings surged 68% and reported quarterly earnings above expectations amid solid growth for blockbuster cancer drug Avastin. But sales of Lucentis, a treatment for age-related blindness, came up short.
Amgen, theworld's largest biotechnology company, said after U.S. markets closed Tuesday that it appointed Robert Bradway as chief financial officer.
Willie Garson proves himself as a celeb to beat, and holds the lead for the 3rd straight day in Trading With The Stars. There was a "flip flop" (no politicians here) of sorts as actor Stephen Collins replaced champion poker player Chris Moneymaker in the second spot--and Chris is in third. All the other celebs are holding their previous places. Actor James Cromwell is showing...
Here's a look at where celeb Judy Gold stands in Trading with the Stars--as chronicled by the crew on "Morning Call," the show she's playing for. She's in 6th place, but DYING to move up a spot or two. Willie Garson still leads the pack after what can only be described as a "tremendous" move up the ranks. (see Timothy Sykes' blog post today).
Here's our update on "Trading With The Stars." Willie proves himself as not another flash in the pan, and maintains the #1 spot two day's in a row. (and just like Willie--almost- Johnny Bench holds onto 7th place!) Interesting note: all of our celeb portfolios are above the $1 million benchmark. Congrats to all for that!!
Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.
The Lightning Round is back, and the callers are especially revved up. Cramer's got the word on Akamai, Cheesecake Factory and a lot more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks closed slightly higher Friday, finishing a week with gains of more than 3% in major market indices. "I like to see this pretty tight trading range; the fact that we've been able to hold on to these gains is healthy," Craig Columbus, chief market strategist at Advanced Equities Asset Management, told CNBC.com.
Sun Micro, Vodafone, Six Flags and more: Cramer tells you to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.
Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.
The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.
Today Cramer gives advice on Amgen, Cisco and more. He's also banning two stocks from the Lightning Round!
John from Florida asked about Amgen. This stock is hanging around a 52 week low and was down 4% yesterday on the news that the SEC is probing their anemia drug Aranesp. Given the unstable market conditions we have, I am wondering if 4% was an overreaction and if AMGN is a buy here?
While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.
Cramer tells you what to do with AT&T, Retail Ventures, Choice Hotels and more.
The world's largest biotechnology company posted a net profit of $833 million, or 71 cents a share, compared with $824 million, or 66 cents a share, a year ago.
The findings on Aranesp and colon cancer treatment Vectibix were released late on Thursday, as the world's largest biotechnology company reported a marginal increase in fourth-quarter profit.
Wall Street is undecided so far on where it will start the day though early earnings news and housing data could help set the tone. For now, eBay's strong profits and big stock move is a bright spot lifting the Nasdaq, which bounced higher on a tech rebound yesterday. The Dow, fresh off its 26th high since October, is flattish.